{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd Surges 9.94% to Day's High of Rs 2101 — Outperforms Sector by 9.3 Percentage Points
The Sensex edged lower by 0.03% on 18 Sep 2026, while Emcure Pharmaceuticals Ltd surged 9.94%, hitting a fresh 52-week and all-time high of Rs 2101. This 9.3-percentage-point outperformance over its Pharmaceuticals & Biotechnology sector peers highlights a distinctly stock-specific rally rather than a market-wide lift.
Strong Momentum Meets Stretched Valuations as Emcure Pharmaceuticals Ltd Reaches All-Time High
Emcure Pharmaceuticals Ltd has reached a significant milestone by touching its all-time high price of ₹1,990 on 18 September 2026, reflecting robust market performance and sustained financial strength within the Pharmaceuticals & Biotechnology sector.
Emcure Pharmaceuticals Ltd is Rated Hold
Emcure Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 24 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 September 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.
Emcure Pharmaceuticals Ltd is Rated Hold
Emcure Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 24 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 27 August 2026, providing investors with the most up-to-date view of the company’s performance and outlook.
Emcure Pharmaceuticals Ltd is Rated Buy
Emcure Pharmaceuticals Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 06 August 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 16 August 2026, providing investors with the latest insights into its performance and outlook.
Emcure Pharmaceuticals Ltd Falls 2.19%: 3 Key Factors Driving the Weekly Move
Emcure Pharmaceuticals Ltd experienced a mixed week capped by a sharp decline on the final trading day, closing the week down 2.19% at Rs.1,933.75, underperforming the Sensex which fell 0.37%. The stock hit a new 52-week and all-time high of Rs.2,047.40 on 10 August 2026 before retreating amid valuation adjustments and profit-taking. Institutional interest remains steady, supported by strong financials and improving valuation metrics.
Broad-Based Technical Strength Lifts Emcure Pharmaceuticals Ltd to 52-Week High of Rs 2047.4
With a decisive surge to Rs 2047.4 on 10 Aug 2026, Emcure Pharmaceuticals Ltd has reached a fresh 52-week high, extending its impressive 44.43% rally over the past year. This milestone reflects a confluence of strong technical momentum and sustained price strength, setting the stock apart in a market where the Sensex has struggled to gain ground.
Emcure Pharmaceuticals Ltd Hits All-Time High of Rs 2,047.4 as Momentum Builds Across Timeframes
Extending its recent rally, Emcure Pharmaceuticals Ltd touched a fresh all-time high of Rs 2,047.4 on 10 Aug 2026, outperforming its sector and the broader market with a 1.56% gain on the day against a Sensex decline of 0.25%.
Emcure Pharmaceuticals Ltd: Valuation Shift Signals Renewed Price Attractiveness
Emcure Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from a very expensive to an expensive rating, reflecting a subtle but meaningful change in price attractiveness. This transition, underpinned by adjustments in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, offers investors a fresh perspective on the stock’s relative value within the Pharmaceuticals & Biotechnology sector.
Emcure Pharmaceuticals Gains 1.09%: 3 Key Factors Driving the Move
Emcure Pharmaceuticals Ltd recorded a modest gain of 1.09% over the week ending 7 August 2026, closing at Rs.1,977.10 compared to Rs.1,955.85 the previous Friday. This performance was slightly below the Sensex’s 1.13% rise during the same period, reflecting a mixed but generally positive week marked by a new 52-week and all-time high, strong quarterly results, and an upgrade in investment rating.
Emcure Pharmaceuticals Reports Strong Quarterly Growth, Upgraded to Buy
Emcure Pharmaceuticals Ltd has demonstrated a marked improvement in its financial performance for the quarter ended June 2026, prompting an upgrade in its Mojo Grade from Hold to Buy. The company’s revenue growth, margin expansion, and profitability metrics have all reached record highs, signalling a positive shift in its financial trend after a period of stagnation.
Broad-Based Technical Strength Lifts Emcure Pharmaceuticals Ltd to 52-Week High of Rs 2008
Surging past the Rs 2000 mark for the first time, Emcure Pharmaceuticals Ltd has reached a new 52-week high on 5 Aug 2026, propelled by a confluence of bullish technical indicators and sustained price momentum.
Strong Momentum Meets Stretched Valuations as Emcure Pharmaceuticals Ltd Reaches All-Time High
Emcure Pharmaceuticals Ltd has reached a new all-time high price of ₹2,005.25 on 05 Aug 2026, underscoring the company’s robust performance and sustained growth within the Pharmaceuticals & Biotechnology sector. This milestone reflects a strong upward trajectory supported by solid fundamentals and positive market trends.
Emcure Pharmaceuticals Ltd is Rated Hold
Emcure Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 05 May 2026. However, the analysis and financial metrics presented here reflect the company’s current position as of 05 August 2026, providing investors with an up-to-date view of its fundamentals, returns, and overall market standing.
Emcure Pharmaceuticals Gains 3.94%: 4 Key Factors Driving the Week’s Momentum
Emcure Pharmaceuticals Ltd delivered a solid weekly performance, rising 3.94% from Rs.1,881.65 to Rs.1,955.85 between 27 and 31 July 2026, outpacing the Sensex’s 2.39% gain over the same period. The stock demonstrated sustained bullish momentum, hitting multiple 52-week and all-time highs amid strong technical indicators and robust financial results, despite a minor midweek pullback. This review analyses the key events and price movements shaping Emcure’s week.
Emcure Pharmaceuticals Ltd Hits All-Time High of Rs 1,959.15 as Momentum Builds Across Timeframes
Emcure Pharmaceuticals Ltd has reached a significant milestone by touching an all-time high price of Rs.1,959.15 on 31 July 2026, marking a notable achievement in the company’s market performance within the Pharmaceuticals & Biotechnology sector.
Broad-Based Technical Strength Lifts Emcure Pharmaceuticals Ltd to 52-Week High of Rs 1959.15
With a decisive break above Rs 1959.15 on 31 Jul 2026, Emcure Pharmaceuticals Ltd has reached a fresh 52-week and all-time high, propelled by a confluence of bullish technical indicators and sustained price momentum.
Broad-Based Technical Strength Lifts Emcure Pharmaceuticals Ltd to 52-Week High of Rs 1957.8
With a decisive break above Rs 1957.8 on 28 Jul 2026, Emcure Pharmaceuticals Ltd has reached a fresh 52-week and all-time high, propelled by a confluence of bullish technical indicators and sustained price momentum.
Emcure Pharmaceuticals Ltd Hits All-Time High of Rs 1,946.90 as Momentum Builds Across Timeframes
Emcure Pharmaceuticals Ltd has reached a new all-time high price of Rs 1,946.90 on 28 July 2026, underscoring the company’s robust performance in the Pharmaceuticals & Biotechnology sector. This milestone reflects sustained growth and positive market momentum, with the stock outperforming key benchmarks and demonstrating strong technical and fundamental attributes.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
